ZNF609 KO cell line available to order. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 1 bp insertion in exon 1.
Images
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Form
- Liquid
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 1 bp insertion in exon 1
Alternative names
KIAA0295, ZN609_HUMAN, ZNF 609, Zinc finger protein 609
Recommended products
ZNF609 KO cell line available to order. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 1 bp insertion in exon 1.
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Form
- Liquid
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 1 bp insertion in exon 1
- Disease
- Adenocarcinoma
- Concentration
Properties
- Gene name
- ZNF609
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Handling procedures
- Initial handling guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.- Subculture guidelines
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 2x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
- Culture medium
- DMEM (High Glucose) + 10% FBS
- Cryopreservation medium
- Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Storage
- Shipped at conditions
- Dry Ice
- Appropriate short-term storage conditions
- -196°C
- Appropriate long-term storage conditions
- -196°C
Notes
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
ZNF609 also known as Zinc Finger Protein 609 functions as a transcription factor. It belongs to the Krüppel-associated box (KRAB) zinc finger protein family which consists of proteins important in gene regulation. The molecular mass of ZNF609 is approximately 177 kDa. It expresses in several tissues with higher levels found in embryonic tissues and some adult brain areas highlighting its significance during development.
- Biological function summary
ZNF609 participates in regulating gene expression by binding to specific DNA sequences. It is not known to be part of a complex but often interacts with other transcription factors and co-regulators. Its regulatory function can activate or repress various downstream genes thereby impacting cellular growth and differentiation processes. The protein plays essential roles in neurodevelopment and muscle tissue formation contributing to normal growth and function.
- Pathways
ZNF609 interfaces closely with the Wnt signaling pathway which is essential for cell fate determination and embryogenesis. It also influences the myogenesis regulatory pathway partnering with other proteins like MYOD1 to direct muscle differentiation. These interactions situate ZNF609 in a critical part of the cellular machinery ensuring proper growth and development.
- Associated diseases and disorders
ZNF609 has associations with neurodevelopmental disorders and certain muscular dystrophies. Disruption or mutation of this protein has links to intellectual disability due to its significant role in brain development. In muscular conditions such as congenital myopathies ZNF609 interacts with proteins like DMD (dystrophin) where abnormal function can result in muscle weakness and degeneration. Understanding these connections is vital for therapeutic approaches targeting these conditions.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Sanger Sequencing - Human ZNF609 knockout HeLa cell line (ab265076)
Allele-1: 1 bp deletion in exon 1.
Sanger Sequencing - Human ZNF609 knockout HeLa cell line (ab265076)
Allele-2: 1 bp insertion in exon 1.
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com